Document is current
Any future updates will be listed below
-
Authors
Fu, Siyu
Boers, Ruben G.
Boers, Joachim B.
van der Meeren, Pam E.
Helmijr, Jean
de Weerd, Vanja
Doukas, Michail
Jansen, Maurice
Hansen, Bettina E.
de Wilde, Roeland F.
Sprengers, Dave
Gribnau, Joost
Wilting, Saskia M.
Debes, José D.
Boonstra, Andre
-
Funding
Funding for this research was provided by:
EU Horizon 2020 program (825510)
- License Information
-
More Information
Article History
Received: 24 January 2025
Accepted: 7 May 2025
First Online: 15 May 2025
Declarations
:
: This study was conducted according to the guidelines of the Declaration of Helsinki and the principles of Good Clinical Practice. Due to the partially retrospective nature of this study, written informed consent was not obtained from each patient. Instead, the ethical review board of the Erasmus MC approved this study as it was in accordance with the COREON guidelines (), which describe the use of coded-anonymous residual human tissue for scientific research (METC-2024–0170 and METC-2019–0137).
: Not applicable.
: The authors declare no conflicts of interest or financial interests except for JB, RB and JG, who report being shareholder in Methylomics B.V., a commercial company that applies MeD-seq to develop methylation markers for cancer staging.
